Carolina Calderón-Ochoa, Narek Plamenov-Donchev, Fernando Hernández-Quiñones, Olga Mendoza-López, Luis Carlos Hinojos-Gallardo, Asunción José Longino-Gómez, Raúl Hernádez-Saldaña, Jorge Duque-Rodríguez, María Cecilia Ishida-Gutiérrez
Severe acute respiratory syndrome coronavirus 2 has caused a global pandemic, leading to health, economic, and political crisis. The virus triggers the activation of inflammatory reactants including interleukin-6 (IL-6), ferritin, and C-reactive protein (CRP), causing multiorgan damage, particularly affecting the lungs. Tocilizumab, an IL-6 receptor blocker, has the potential to diminish the progression of the disease and reduce organ damage and long-term complications. The aim of this observational retrospective cohort study was to evaluate the efficacy of tocilizumab in decreasing CRP levels in hospitalized coronavirus disease 2019 (COVID-19) patients compared to standard care without the drug...
April 30, 2024: Microbiology Spectrum